Battle Over Plan B In Virginia Focusing On Minors, Colleges
This article was originally published in The Tan Sheet
Executive Summary
Two bills referred to the Virginia Senate limiting availability of Barr's emergency contraceptive Plan B (levonorgestrel .75 mg) could predict similar legislative action in the future
You may also be interested in...
Plan B Switch Decision Deadline Postponed To May
An FDA decision on the Rx-to-OTC switch of emergency contraceptive Plan B (levonorgestrel .75 mg) has been pushed back from February 20 to May 20
House Representatives Worried OTC Plan B May Increase Adolescent STD Risk
Political pressure could affect the pending FDA decision on Barr Labs' application for over-the-counter status for emergency contraceptive Plan B (levonorgestrel)
Plan B Behind-The-Counter Status Discouraged By Panel Members
Barr Labs' Plan B (levonorgestrel) emergency contraceptive was recommended for over-the-counter in a 23-4 vote by the Nonprescription Drugs and Reproductive Health Drugs Advisory Committees at a joint meeting Dec. 16 in Gaithersburg, Md. The joint panel rejected behind-the-counter status for the product